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Abstract
Regulatory T cells (Treg), formerly known as suppressor T cells, are essential for maintaining self-
tolerance as well as immune homeostasis. Lack of Treg or normal function of Treg often leads to
lymphoproliferative syndrome and autoimmunity in human and mouse. The chromatin remodeling
BAF complex regulates gene expression through the activity of Brg. Genetic ablation of Brg gene
in mouse resulted in early embryonic lethality. T cell failed to develop in the thymus when Brg is
deleted at DN stage. Using a Brg conditional KO mouse model, we deleted Brg at the DP stage in
the thymus. Unexpectedly, T cells developed and matured normally. However, these mice displayed
lympho-proliferative syndrome 2–4 months of age with enlarged peripheral lymphoid organs and
leukocyte infiltration in non-lymphoid organs. T cells from these mice turned into effector cells
producing increased amounts of effector cytokines as early as 4 weeks after birth. Further analysis
revealed that the Treg population was specifically affected by Brg deletion. In this mini-review, we
will discuss in detail the properties of Tregs controlled by Brg and the potential underlying
mechanisms for an unanticipated, specific role of the Brg-containing BAF complex in controlling
Treg functions.
Treg, its function and regulation
In 1995, a subset of T cells that actively suppressed immune responses were identified [1].
These cells, later referred to as regulatory T cells (Treg), are critical for maintaining self-
tolerance and controlling immune responses. Defective Treg function invariably leads to
autoimmunity or inflammatory diseases in human and mouse [2–5].
Based on the expression profiles of cell surface molecules and/or cytokines, several types of
Tregs have been categorized [2]. Among them, naturally occurring Treg (nTreg) is the best
characterized and studied. nTreg is a subset of CD4 T cells that develop in the thymus and
constitutively express high levels of IL-2 receptor α chain (CD25) on the cell surface. nTregs
comprise approximately 10% of peripheral CD4 T cells in mice and humans. In the absence
of functional nTregs, systemic autoimmune syndrome develops in IPEX patients and Scurfy
mice, underscoring the critical function of nTreg in self-tolerance [3,4]. A set of cell surface
molecules besides CD25, such as cytotoxic T lymphocyte antigen-4 (CTLA-4), glucocorticoid-
induced tumor necrosis factor receptor family related gene (GITR) and lymphocyte activation
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antigen-3 (LAG-3) have also been used to differentiate nTreg from conventional T cells [2].
TGF-β and IL-10, potent immune suppressive cytokines, are highly expressed in Tregs [6–
10]. Although these genes are constitutively expressed at high levels in nTreg, they are also
highly expressed in conventional T cells under certain conditions. In addition, although these
genes contribute to the function of Tregs, none of them appears to be specifically involved in
the generation and function of Treg cells. It was not until early 2000 that Foxp3, an X-linked
transcription factor belonging to the fork-head family, was found to be specifically and highly
expressed in nTregs [11–15]. More importantly, single gene inactivation of Foxp3 accounts
for the loss of functional Treg cells and the development of IPEX in human patients and the
Scurfy phenotype in mice [11,12]. In addition, forced expression of Foxp3 in non-Treg T cells
endows suppressive activities [16,17]. Thus, a high level of Foxp3 now serves as a surrogate
marker for functional Treg cells. Multiple reporter mouse strains have been developed to mark
Foxp3 expressing cells [18–20], fueling our intense efforts of understanding how Treg function
is controlled.
The existence of adequate numbers of functional Treg cells is essential for self-tolerance and
immune homeostasis. Thus, perturbation of the generation, maintenance and the function of
Tregs often lead to over-exuberant immune responses and immune pathology. High level
expression of CTLA-4 and IL-10 contribute to the suppressive function of Treg without
affecting its generation or maintenance [21]. On the other hand, IL-2 and its signaling
components promote and PDE3B inhibits the peripheral maintenance but not the function of
Treg cells [22,23]. TGF-β however regulates both the function and maintenance of Treg cells
[24]. Therefore, it appears that multiple genes and signaling pathways are involved in the
regulation of Treg maintenance as well as function. Substantial efforts are being devoted to
unravel the mechanisms on how different aspects of Treg physiology are regulated. The hunt
for genes that specifically regulate Treg function is warranted. Such studies are not only
essential for the understanding of Treg function, but also for elucidating the etiology of human
immune diseases, such as autoimmunity and cancer, and for devising effective therapies to
treat these illnesses.
Chromatin remodeling and its function in T cells
In eukaryotes, genomic DNA associates with the nuclear protein complex known as chromatin.
The basic repeating unit of chromatin is the “nucleosome core particle” where a histone
octamer, consisting of 8 histone molecules of 4 types (two each of H2A, H2B, H3 and H4),
grips and sequesters a 146-bp DNA segment. An array of linked nucleosome particles can be
progressively coiled up into condensed fibers, effectively “burying” DNA. Such a structure on
one hand protects DNA from harmful exposure to the myriads of proteins and enzymes in the
nucleus. On the other hand, it prevents nuclear factors to access genes to regulate their
expression.
To reconfigure chromatin, cells often mobilize “chromatin remodeling complexes” (CRC) that
use energy to disrupt histone-DNA contacts. CRC are powerful molecular motors that use
mechanical force derived from ATP hydrolysis to disrupt histone-DNA contacts, exposing
nucleosomal DNA. Multiple classes of CRC have been isolated in eukaryotic cells, each of
which contains a related ATPase as the motor subunit. The best-defined mammalian CRC is
the “BAF complex”, a 10 subunit complex. Two ATPase subunits, Brg (Brahma-related gene)
and Brm (Brahma) are found in mammalian cells to assemble into alternative BAF complexes
[25,26] (hence the name Brg/Brm Associated Factor or BAF complex) [27]. The expression
patterns of Brg and Brm are distinct: Brg is constitutively and ubiquitously expressed
throughout development, while Brm is expressed predominantly in mature, differentiated cells
[28,29]. The function of Brg and Brm are similar and yet divergent [28–32]. To regulate gene
expression, CRCs often associates with Histone Acetyl Transferases (HATs) [33], histone
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methylase [34], or Histone Deacetylases (HDAC) [35–37]. BAF complexes can be transiently
recruited to and remodel a promoter to mediate gene induction in response to signaling, but
can also constitutively remodel a promoter to poise it for rapid induction in anticipation of
signaling.
Over the past few years, genetic and biochemical approaches have been used to address the
roles of BAF complex in the immune system. T cell-specific inactivation of Brg containing
BAF complex indicates that they are essential for thymocyte developmental transitions, and
that they contribute to CD4/CD8 lineage bifurcation by directly repressing CD4 while
activating CD8 expression [29,32,38]. A role of Brg in VDJ recombination has been proposed
based on the fact that Brg stimulates recombination on chromatin templates in vitro, and that
Brg is selectively bound to the TCR loci open for recombination [39–43]. Brg is also critical
for innate and adaptive immune responses [44–46]. Thus, in the immune system, BAF complex
possesses quite diverse functions to regulate different cell types.
Brg function during late T cell development and in mature T cells
We have been interested in studying the roles of BAF complex in the function and gene
regulation in different compartments of T cells. The failure of T cell generation in LckCre
Brgflox/− mice, where the Brg gene was deleted during the DN stage of thymocyte development
[29], prevented us from studying its role in mature T cells. In hope of circumventing this, we
crossed CD4Cre transgenic mice with Brgflox/− mice to obtain CD4Cre- Brgflox/− mice; thus
Brg is deleted in DP thymocytes and later. Normal thymocyte development was observed when
Brg is deleted in the DP stage (our unpublished results). As comforting as it is, this result is
surprising in that our previous study demonstrated that Brg is essential for DN thymocyte
survival as well as developmental progression [29], indicating a role for Brg in controlling T
cell survival and proliferation. This intriguing result provides evidence to support the notion
that Brg function is intricately regulated during T cell development; Brg is essential for specific
but not all stages of T cell development. Despite the largely normal T cell development in these
mice, we observed lymphadenomegaly and splenomegaly with increased lymphocyte counts
in older mice. In addition, T cells from these mice gained activated phenotype. One of the
possible causes of such a phenotype could be defective Treg function. To test this hypothesis,
we analyzed and compared the numbers of Foxp3+ Treg cells in the periphery between Brg
deficient and WT mice, and no substantial difference was observed. In vitro, the suppression
activities of BrgKO appeared to be normal. In addition, the expression of Treg “signature”
genes was also normal. However, in vivo, BrgKO Treg cells did not protect naïve T cell elicited
colitis in Rag1−/− mice. This was because Brg deficient Treg cells failed to be maintained in
the periphery after transfer. However, conventional T cells lacking the Brg gene were
maintained normally in the periphery. These results suggest a specific role for Brg in promoting
Treg maintenance in vivo. Bone marrow chimera mice, where WT and Brg−/− T cells coexisted
in the same physiological environment, were also created. In accordance with our previous
results, lower percentage of Treg cells were detected from Brg−/− CD4 T cells compared to
those detected from WT cells. Oligo-array assays were performed to identify genes specifically
dependent on Brg in Treg cells. Less than 50 genes were significantly affected by Brg deletion.
Among them, genes involved in cell survival, metabolism and TGF-β signaling were identified.
Therefore, these new findings demonstrated an unexpected, specific role for Brg in controlling
Foxp3+ Treg peripheral maintenance likely through promoting its survival.
How one CRC specifically regulates gene expression in a cell type and context dependent
manner is an important question and warrants further investigation. Revelation of the specific
roles of CRC in different cell types will surely enhance the understanding of gene regulation
mechanisms and its relevance for normal physiological functions.
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